A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants

Phase 1 Completed 50 enrolled DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company Eli Lilly and Company · collab

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to assess the effect of multiple doses of itraconazole, fluconazole, and carbamazepine on single dose pharmacokinetic of LY4100511 (DICE-853) in healthy participants. The study will also evaluate the safety and tolerability of LY4100511 (DICE-853) with itraconazole, fluconazole, and carbamazepine.

Timeline

Start: 2024-04-03
Primary completion: 2024-06-18
Completion: 2024-06-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carbamazepine	Small molecule	—	Oral
Subject	Fluconazole	Small molecule	—	Oral
Subject	Itraconazole	Small molecule	—	Oral
Subject	LY4100511	Unknown	—	Oral

Indications

No indication recorded.